Application no. and date | 14835826.0 (espacenet) (Federated) (European Patent Register), 20140807 | Patent/reg. no. and date | DK/EP 3033101, 20181219 | Publication date | 20160622 | Priority no. and date | US 201361864944 P, 20130812 | EP pub. no. and date |
EP 3033101 20160622 | Effective date | | Applicant/owner | AstraZeneca AB,
151 85 Södertälje, SE | Applicant ref. no. | AST IL5R-603-EP-EPT | Inventor | WARD, Christine, C/o Medlmmune Llc One Medlmmune Way
Gaithersburg, MD 20878, US, ROSKOS, Lorin, C/o Medlmmune Llc One Medlmmune Way
Gaithersburg, MD 20878, US, WANG, Bing, C/o Medlmmune Llc One Medlmmune Way
Gaithersburg, MD 20878, US, RAIBLE, Donald, 317 Lenape Drive
Berwyn, PA 19312, US | Representative | RWS Group, RWS Compass House
Vanwall Business Park, Vanwall Road
Maidenhead, Berkshire
SL6 4UB, GB | Opponent | | IPC Class | A61K 39/00 (2006.01) , A61K 39/395 (2006.01) , C07K 16/24 (2006.01) , G01N 33/48 (2006.01) | Title | FREMGANGSMÅDER TIL REDUCERING AF EKSACERBATIONSRATER FOR ASTMA VED ANVENDELSE AF BENRALIZUMAB | Int. application no. | US2014050080 | Int. publication no. | WO2015023504 | Related patent (certificate) | | Status | DK/EP patent | Pædiatrisk forlængelse | - | Udløbsdato for pædiatrisk forlængelse | - |
|